Policy & Regulation
Antios Therapeutics commences hepatitis B drug clinical trial
13 February 2020 -

Antios Therapeutics Incorporated, a clinical-stage biopharmaceutical company announced on Wednesday that it has started its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B.

The Phase Ia study is a randomised, double-blind, placebo-controlled single-ascending dose study in healthy volunteers to assess the compound's safety, tolerability and pharmacokinetic profile.

This single-ascending dose study will be conducted in up to 35 healthy subjects randomised into five cohorts of seven subjects each. A Phase Ib multiple-ascending dose clinical study in HBV-infected patients is planned to start following the completion of the single-ascending dose and multiple-ascending dose cohorts for the Phase Ia study.